Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

作者：Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Neha Mehta–Shah, Kaiyang Ding, Yao Liu, Zengjun Li, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yue-Rong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin Zhai, Liqun Zou, Yaming Xi, Youngil Koh, Fei Li, Miles Prince, Hui Zhou, Lie Lin, Hui Liu, Pamela B. Allen, Fernando Roncolato, Zhenfan Yang, Won-Seog Kim, Jun Zhu · 发表于：The Lancet Oncology · 年份：2023 · DOI：10.1016/s1470-2045(23)00589-2 · 被引用次数：61 · 研究领域：Lymphoma Diagnosis and Treatment、T-cell and Retrovirus Studies、Cutaneous lymphoproliferative disorders research